- Home
- NWFL vs LRMR Comparison
NWFL vs LRMR Comparison
Compare NWFL & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NWFL | LRMR |
|---|---|---|
| Founded | 1870 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.0M | 280.0M |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NWFL | LRMR |
|---|---|---|
| Price | $28.55 | $5.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $33.00 | $16.29 |
| AVG Volume (30 Days) | 19.6K | ★ 6.5M |
| Earning Date | 04-22-2026 | 04-14-2026 |
| Dividend Yield | ★ 4.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.22 | N/A |
| Revenue | ★ $7,399,000.00 | N/A |
| Revenue This Year | $34.35 | N/A |
| Revenue Next Year | $5.55 | N/A |
| P/E Ratio | $13.00 | ★ N/A |
| Revenue Growth | ★ 3.69 | N/A |
| 52 Week Low | $21.25 | $1.61 |
| 52 Week High | $32.23 | $6.42 |
Technical Indicators
Market Signals| Indicator | NWFL | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 38.49 | 62.97 |
| Support Level | $27.50 | $3.18 |
| Resistance Level | $29.58 | $6.42 |
| Average True Range (ATR) | 0.90 | 0.57 |
| MACD | -0.23 | 0.11 |
| Stochastic Oscillator | 5.21 | 74.76 |
Price Performance
Historical ComparisonAbout NWFL Norwood Financial Corp.
Norwood Financial Corp is a U.S.-based bank holding company. It offers various personal and business credit services, trust and investment products, and real estate settlement services to consumers, businesses, nonprofit organizations, and municipalities in each of the communities that the bank serves. The bank also manages automated teller machines at its branch location. It serves the Pennsylvanian counties of Wayne, Pike, Monroe, and Lackawanna, as well as Susquehanna County.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.